Antibody therapeutics that bind TIM3
There is disclosed compositions and methods relating to or derived from anti-TIM3 antibodies. More specifically, there is disclosed fully human antibodies that bind TIM3, TIM3-antibody binding fragments and derivatives of such antibodies, and TIM3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
1. An isolated fully human anti-TIM3 antibody of an IgG class that binds to a TIM3 epitope, wherein said antibody comprises:
a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO. 5 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO. 6; or
a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO. 35 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO. 36.
2. The fully human antibody of claim 1 , wherein the antibody has a KD of at least 1×10 −6 M.
3. An anti-TIM3 fully human antibody fragment comprising:
a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO. 5 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO. 6; or
a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO. 35 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO. 36;
wherein the fragment is a single chain antibody comprising a peptide linker connecting the heavy and light chain variable domains, or a Fab fragment.
4. The fully human antibody Fab fragment of claim 3 , wherein the antibody has a KD of at least 1×10 −6 M.
5. An isolated anti-TIM3 antibody, or an antigen-binding fragment thereof, comprising:
a heavy chain variable domain comprising complementarity determining regions (CDRs) as set forth in the heavy chain variable domain amino acid sequence of SEQ ID NO. 5 and a light chain variable domain comprising CDRs as set forth in the light chain variable region amino acid sequence of SEQ ID NO. 6; or
a heavy chain variable domain comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO. 35 and a light chain variable domain comprising CDRs as set forth in the light chain variable region amino acid sequence of SEQ ID NO. 36.
6. The antibody, or antigen-binding fragment thereof, of claim 5 , which has a KD of at least 1×10 −6 M.
7. A pharmaceutical composition comprising the anti-TIM3 antibody or antibody fragment thereof of claim 5 , and a pharmaceutically acceptable carrier.